Loading viewer...
other
Format: PDF other
Plainview LLC short-seller report from October 2018 arguing that Nektar Therapeutics' NKTR-214 immunotherapy candidate lacks efficacy and misses clinical thresholds. The report claims the drug's mechanism does not achieve stated objectives and compares results unfavorably to competing candidates like epacadostat.
conference
28 Pages
29 Pages
ΤΙΤΑΝ
Bespoke Investment Report January 2017 Market Analysis
otherother
38 Pages
Bespoke Investment Group